<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865356</url>
  </required_header>
  <id_info>
    <org_study_id>SP14019-18</org_study_id>
    <nct_id>NCT02865356</nct_id>
  </id_info>
  <brief_title>Topical Solution for the Treatment of Atopic Dermatitis</brief_title>
  <acronym>CYCLATOP</acronym>
  <official_title>Evaluation of SP14019-F-01 Topical Solution for the Treatment of Atopic Dermatitis. Pilot Study (CYCLATOP STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spherium Biomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen Macarena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario de Alicante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spherium Biomed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a proof of concept, multi-center, randomized, double-blind and&#xD;
      vehicle-controlled study with intra-individual comparison of treatments.&#xD;
&#xD;
      Three age cohorts of patients will be included in the study according to the following age&#xD;
      ranges:&#xD;
&#xD;
        1. ≥18 years old (minimum 6, maximum 18 patients)&#xD;
&#xD;
        2. &gt;12 - 17 years old (minimum 6, maximum 18 patients)&#xD;
&#xD;
        3. &gt;2 - 12 years old (minimum 6, maximum 18 patients)&#xD;
&#xD;
      The main objectives of study are:&#xD;
&#xD;
      To assess the efficacy of SP14019-F-01 topical solution (5% cyclosporine A [CsA]) compared to&#xD;
      placebo topical solution for the treatment of patients with mild to moderate atopic&#xD;
      dermatitis (AD).&#xD;
&#xD;
      To evaluate the safety and tolerability of SP14019-F-01 (5% CsA) topical solution in patients&#xD;
      with mild to moderate AD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a proof of concept, multi-center, randomized, double-blind and&#xD;
      vehicle-controlled study with intra-individual comparison of treatments. CsA plasma&#xD;
      concentration assessments will be carried out at Visit 0 predose, and Visits 1 and 4 of the&#xD;
      study period.&#xD;
&#xD;
      Three age cohorts of patients will be included in the study according to the following age&#xD;
      ranges:&#xD;
&#xD;
        1. ≥18 years old (minimum 6, maximum 18 patients)&#xD;
&#xD;
        2. &gt;12 - 17 years old (minimum 6, maximum 18 patients)&#xD;
&#xD;
        3. &gt;2 - 12 years old (minimum 6, maximum 18 patients) The study will close when the total&#xD;
           of 36 patients has been included among all age groups and the minimum number of 6&#xD;
           patients has been reached for each age group.&#xD;
&#xD;
      Before including paediatric population, a minimum of 6 adult patients should complete the&#xD;
      treatment to assess the safety profile.&#xD;
&#xD;
      A randomized list will be created to determine in which side of the body (left or right) the&#xD;
      subject will apply each medication (SP14019-F-01 topical solution [5% CsA] or SP14019-F-02&#xD;
      vehicle-control placebo solution). Solutions will be applied twice daily for four complete&#xD;
      weeks (28 days) in all affected areas.&#xD;
&#xD;
      Photography will be used to record the evolution of the lesions at Visits 0 (pre-1st dose),&#xD;
      Visits 1, 2, 3, 4 and follow-up.&#xD;
&#xD;
      The main objectives of study are:&#xD;
&#xD;
      To assess the efficacy of SP14019-F-01 topical solution (5% cyclosporine A [CsA]) compared to&#xD;
      placebo topical solution for the treatment of patients with mild to moderate atopic&#xD;
      dermatitis (AD).&#xD;
&#xD;
      To evaluate the safety and tolerability of SP14019-F-01 (5% CsA) topical solution in patients&#xD;
      with mild to moderate AD.&#xD;
&#xD;
      A Steering Committee will convene periodically to maintain the quality of study conduct, and&#xD;
      to discuss any major issues or concerns and with particular attention to some critical events&#xD;
      which may lead to stop the recruitment. These critical events are the observation of either&#xD;
      new unexpected signals on safety related to CsA. The Steering Committee will also evaluate&#xD;
      the safety profile of the treatment before including paediatric population&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">April 12, 2017</completion_date>
  <primary_completion_date type="Actual">April 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline (Day 0) of Eczema Area and Severity Index (EASI) score of the treated body area (CsA vs Vehicle control placebo)</measure>
    <time_frame>Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline (Day 0) of Investigator's Global Assessment (IGA) score (on a 0 to 4-point scale; CsA vs Vehicle control placebo)</measure>
    <time_frame>Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change from baseline (Day 0) of Atopic Dermatitis Severity Index (ADSI) score (Cs vs Vehicle control placebo)</measure>
    <time_frame>Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (TEAEs).</measure>
    <time_frame>From date of randomization (Day 0) until 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of TEAEs leading to study drug discontinuation</measure>
    <time_frame>From date of randomization (Day 0) until 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CsA plasma concentrations</measure>
    <time_frame>From date of randomization (Day 0) up to 4 weeks, on day 7 and 28.</time_frame>
    <description>samples obtained just before the first daily dose (around 8 am) on Visits 0, 1 and 4 to check the absence of systemic absorption during the period of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cyclosporine 5% Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas.&#xD;
A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas.&#xD;
A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine 5% solution</intervention_name>
    <description>topical solution</description>
    <arm_group_label>Cyclosporine 5% Solution</arm_group_label>
    <other_name>ciclosporin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>topical vehicle solution</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>SP14019-F-02 Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged between 2 and 75 years, inclusive, at the screening visit. 2. AD&#xD;
             diagnosis according to the Hanifin/Rajka criteria with one eczema outbreak at the&#xD;
             screening and baseline.&#xD;
&#xD;
             3. Presence of at least two lesional areas. These areas should be at the left and&#xD;
             right side of the body and occupying a body surface area (BSA) in each side between&#xD;
             0.1% and 10% of the BSA. IGA score of the two sites not differ by more than 1 point.&#xD;
&#xD;
             4. Mild to moderate disease severity of AD defined by an IGA score of 2 or 3 at&#xD;
             baseline (IGA scale from 0 to 4).&#xD;
&#xD;
             5. Total BSA of AD involvement ≤ 10% in each side of the body (≤ 20% maximum). 6.&#xD;
             Normal weight as defined by a Quetelet Index (Body Mass Index [BMI]: weight in kg&#xD;
             divided by the square of height in meters) of 18.0 to 30.0 kg/m2 (both included).&#xD;
&#xD;
             7. General medical condition, in the investigator's opinion, does not interfere with&#xD;
             the assessments and the completion of the trial.&#xD;
&#xD;
             8. Parent's or legal guardian's written informed consent and child assent, if&#xD;
             appropriate or patient's inform consent for patients ≥ 18 years of age before any&#xD;
             assessment is performed.&#xD;
&#xD;
             9. Able to communicate with the investigator and comply with the requirements of the&#xD;
             study (for children the parent can assist when necessary).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Female subject of childbearing potential without use of effective birth control&#xD;
             methods, or not willing to continue practicing these birth control methods for at&#xD;
             least 30 days after the end of the treatment period;&#xD;
&#xD;
        Note: Estrogen based hormonal contraception may not be reliable when SP14019-F-01 topical&#xD;
        solution is applied, therefore to be eligible for this trial, women of childbearing&#xD;
        potential should either:&#xD;
&#xD;
          1. use a double barrier method to prevent pregnancy (i.e., using a condom with either&#xD;
             diaphragm or cervical cap);&#xD;
&#xD;
          2. use hormonal based contraceptives in combination with a barrier contraceptive (i.e.,&#xD;
             male condom, diaphragm or cervical cap, or female condom);&#xD;
&#xD;
          3. use an intrauterine device in combination with a barrier contraceptive (i.e., male&#xD;
             condom, diaphragm or cervical cap, or female condom);&#xD;
&#xD;
          4. be only non-heterosexually active, practice heterosexual abstinence, or have a&#xD;
             vasectomized partner (confirmed sterile). Women with tubal ligation are required to&#xD;
             use 1 non-hormonal contraceptive method.&#xD;
&#xD;
             Women who are postmenopausal for at least 2 years, and women with total hysterectomy&#xD;
             are considered of non-childbearing potential. Males with partners of childbearing&#xD;
             potential should inform them of their participation in this clinical study and use a&#xD;
             highly effective method of birth control during the study.&#xD;
&#xD;
             2. Pregnant woman or with a positive pregnancy test or breast feeding at baseline.&#xD;
&#xD;
             3. Any condition in the lesions that in the opinion of the investigator could&#xD;
             interfere with clinical assessments, e.g. acne, infection, rash other than AD,&#xD;
             sunburn, scars, hairy or tattooed area.&#xD;
&#xD;
             4. Patients receiving phototherapy or systemic therapy for AD within 4 weeks before&#xD;
             the first application of trial medication.&#xD;
&#xD;
             5. Patients receiving antibiotics, topical therapy for AD within 2 weeks before the&#xD;
             first application of trial medication.&#xD;
&#xD;
             6. Patients taking antihistamines within 1 week before the first application of trial&#xD;
             medication.&#xD;
&#xD;
             7. Patients receiving radiation therapy, systemic therapy with cytostatics or&#xD;
             biological therapy within 24 weeks before the first application of trial medication,&#xD;
             or with previous history of malignancy (excluding basal cell carcinoma).&#xD;
&#xD;
             8. Patients with any acute skin infection (superinfection or secondary&#xD;
             impetiginisation).&#xD;
&#xD;
             9. Patients with confirmed hypertension, renal disease or serious infections at&#xD;
             screening.&#xD;
&#xD;
             10. Any currently active allergy such as but not limited to drug allergy, food allergy&#xD;
             or hay fever.&#xD;
&#xD;
             11. Previously demonstrated clinically significant allergy or hypersensitivity to any&#xD;
             of the excipients of the trial medication administered in this trial.&#xD;
&#xD;
             12. Participation in an investigational drug trial within 30 days prior to the first&#xD;
             application of trial medication.&#xD;
&#xD;
             13. Any condition (including but not limited to alcohol and drug use), which in the&#xD;
             opinion of the investigator could compromise the patient safety or compliance with&#xD;
             trial procedures.&#xD;
&#xD;
             14. Subjects who have received or are planning to receive any vaccination within 28&#xD;
             days prior to the first dose of study medication, or planning to receive a vaccination&#xD;
             during the course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Ferrándiz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <keyword>eczema</keyword>
  <keyword>children</keyword>
  <keyword>skin</keyword>
  <keyword>topical</keyword>
  <keyword>cyclosporine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

